ArabFinance: Arab Drug Company (ADCI) targets generating a net profit of EGP 112.375 million during the fiscal year (FY) 2022/2023, according to the company's estimated income statement filed to the Egyptian Exchange (EGX) on May 16th.

The company's estimated total operating revenues for FY 2022/2023 stand at EGP 698.1 million.

It is worth noting that Arab Drug’s net profit after tax reached EGP 68.52 million during the period from July 1st 2021 until March 31st 2022, down from EGP 81.23 million in the same period a year earlier.

Arab Drug is an Egypt-based company engaged in the pharmaceutical sector. The company focuses on the manufacture, packaging, and distribution of pharmaceutical products as well as chemical solutions for human and veterinary use.